AUG 2 6 2008 PTO/SB/21 (08-08)
Approved for use through 08/31/2008. OMB 0861-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, n	o persons are required to respond to a colle		mation ur	nless it d	isolava a valid OMB control number.	
		10/767,813				
TRANSMITTAL	Filing Date	JANUARY 29, 2004				
FORM	First Named Inventor	ZHANG ET AL.				
	Art Unit	1614		·,		
(to be used for all correspondence after initial fill	Examiner Name	T. BETTON				
Total Number of Pages in This Submission 3	Attorney Docket Number	AHPWA1DUSA				
ENCLOSURES (Check all that apply)  After Allowance Communication to TC						
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application  Reply to Missing Parts  under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A  Terminal Disclaimer Request for Refund CD, Number of CD(s)  Landscape Table on CD  Remarks	vddress		Appeal of Appeal (Appeal (Appeal Proprie	Communication to Board late and Interferences Communication to TC Notice, Brief, Reply Brief) tary Information Letter Enclosure(s) (please Identify	
SIGNAT	TURE OF APPLICANT, ATTO	RNEY, O	R AGE	NT		
Firm Name HOWSON & HOWSON LL	Р 🔷	<u></u>				
Shanature ()						
Printed name Printed name						
TRACYLL BALOVICH						
Date 8-26-2008		Reg. No.	47,840			
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature S C C						
Typed or printed name SUMMER UCHIN	<u> </u>			Date	8-26-2008	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Comfidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Ø 002/003

## AUG 2 6 2008

**AHPWAIDUSA** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/767,813

Confirmation No.: 5696

**Applicant** 

: Zhang et al.

Filed

: January 29, 2004

TC/A.U.

: 1614

Examiner

: T. Betton

Customer No.

: 38199

Title

: CYCLOCARBAMATE DERIVATIVES AS

PROGESTERONE RECEPTOR MODULATORS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## LETTER

Sir:

This paper is filed to submit a replacement Terminal Disclaimer in an effort to correct a clerical error. Specifically, the below-noted agent of record incorrectly referenced US Patent No. 6,556,358 and not co-owned US Patent No. 6,566,358 in one (1) Terminal Disclaimer filed on April 2, 2008. Applicants respectfully request that the Examiner withdraw the Terminal Disclaimer over US Patent No. 6,556,358 filed on April 2, 2008 with the attached Terminal Disclaimer over co-owned US Patent No. 6,566,358.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON & HOWSON

Tracy U. Palovich, PhD Registration No. 47,840 501 Office Center Drive

Suite 210

Fort Washington, PA 19034 Telephone: 215-540-9200

Facsimile: 215-540-5818

## RECEIVED **CENTRAL FAX CENTER**

AUG 2 6 2008 PTO/SBI28 (01-08)
Approved for use through 04/30/2008; OMB 0661-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unbass it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) AHPWA1DUSA
In re Application of: ZHANG et al.	
Application No.: 10/767,813	
Filed: JANUARY 29, 2004	
For: CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS	
The owner*, <u>WYETH</u> , of <u>100</u> percent interest in texcept as provided below, the terminal part of the statutory term of any patent granted on the instant the expiration date of the full statutory term prior patent No. <u>8,568,358</u> as the term of said and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The granted on the instant application shall be enforceable only for and during such period that it and the pagreement runs with any patent granted on the instant application and is binding upon the grantee, its said the pagreement runs with any patent granted on the instant application and is binding upon the grantee.	prior patent is defined in 35 U.S.C. 154 winer hereby agrees that any patent so prior patent are commonly owned. This
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any paten would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the patent is presently shortened by any terminal disclaimer," In the event that said prior patent later: expires for fallure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened in	prior patent, "as the term of said prior
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university etc.), the undersigned is empowered to act on behalf of the business/organization.  I hereby declare that all statements made horsen of my own knowledge are true and that a belief are believed to be true; and further that these statements were made with the knowledge that made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United statements may jeopardize the validity of the application or any patent issued thereon.	Il statements made on information and willful false statements and the like so
2. The undersigned is an attorney or agent of record, Reg. No. 47,840	
Sury (9. Falaxel) Signature	<u>€-26-200</u> ₽
TRACY U. PALOVICH	
Typed or printed name	
•	215-540-9200
Terminal disclaimer fee under 37 CER 1 20(d) included	Telephone Number
Common dissenses see and 57 Of IC 1,20(0) (IIMIGGG).	
WARNING: Information on this form may become public. Credit card inform be included on this form, Provide credit card information and authorization	ation should not on PTO-2038.
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, propering, and submitting the complete application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.